According to GlobalData’s medical device pipeline database, 19 BRAF Tests devices are in various stages of development globally. GlobalData’s report BRAF Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, six are in active development, while the remaining 13 are in an inactive stage of development. There are three products in the early stages of development, and the remaining three are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. A BRAF test is a type of genetic test that looks for a change, known as a mutation, in a gene called BRAF. BRAF tests are most commonly used to look for BRAF mutations in patients with melanoma, a type of skin cancer. However, BRAF mutations have also been found in other types of cancer, including colorectal cancer, lung cancer, and thyroid cancer. There are two main types of BRAF tests: DNA sequencing and immunohistochemistry (IHC).
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed BRAF Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of BRAF Tests devices. Overall, most of these BRAF Tests pipeline devices are being developed by private entities.
Key players involved in the active development of BRAF Tests include Abbott Diagnostics, Amoy Diagnostics, Exosomics Siena, GenomicTree, Memorial Sloan Kettering Cancer Center, MolecularMD, Qiagen, QuantuMDx Group, Seegene and Syamala Srinivasa Life Sciences Pvt..
For a complete picture of the developmental pipeline for BRAF Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
